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In this nationwide, population-based study, we assessed trends in primary treatment
and survival among 687 patients with nodular lymphocyte-predominant Hodgkin
lymphoma (75% males; median age, 40 years; and 74% stage-I/II disease) diagnosed
in the Netherlands between 1993–2016. There were no noteworthy changes in the
application of primary therapy over time among adult patients across the different
disease stages and age groups. Survival among various subgroups of adult patients
was largely comparable to the expected survival of the general population. A partic-
ularly encouraging finding was that young adult patients experienced virtually no
excess mortality, as compared to the general population.
Keywords: nodular lymphocyte-predominant Hodgkin lymphoma
(NLPHL), cancer epidemiology, population-based registry, incidence, sur-
vival.
Nodular lymphocyte-predominant Hodgkin lymphoma
(NLPHL) is a rare, distinct subtype of Hodgkin lymphoma
(HL). It differs substantially from classical HL regarding clin-
ical, immunological, and histological characteristics (Anag-
nostopoulos et al., 2000). Also, the management of NLPHL
varies from classic HL, especially for patients with limited-
stage NLPHL in whom radiotherapy is generally indicated
(Eichenauer et al., 2018; Spinner et al., 2019). Furthermore,
the universal expression of CD20 in NLPHL led to the incor-
poration of rituximab into treatment algorithms around
2003 (Eichenauer et al., 2011).
Evidence to guide treatment decision-making in NLPHL
has come from the few prospective and retrospective studies
performed over the past decades (Chen et al., 2010; Alonso
et al., 2018). Therefore, it is reasonable to assume that
NLPHL management might vary across time and geography.
In this regard, population-based studies can provide insights
on how treatment practices over time affect the population-
level survival of patients. For example, the few published
population-based studies in NLPHL provide conflicting
results about the effect of rituximab on survival (Molin
et al., 2017; Shivarov & Ivanova, 2018). These studies,
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however, have their limitations, including small sample sizes,
lack of detailed treatment information, or a short length of
follow-up.
Given the scarcity of clinical and population-based studies
in NLPHL, we conducted a large, contemporary, nationwide
population-based study to assess trends in primary treatment
and survival among NLPHL patients diagnosed during a 24-
year period in the Netherlands.
Methods
We selected all 687 NLPHL patients diagnosed between 1993
and 2016 — with survival follow-up through February 2018
— from the nationwide population-based Netherlands Can-
cer Registry (NCR) using the International Classification of
Diseases for Oncology morphology code 9659 that was intro-
duced in 1993. Established in 1989, the NCR has a coverage
of >95% of all newly diagnosed malignancies in the Nether-
lands (Schouten et al., 1993). Information on dates of birth
and diagnosis, sex, stage, vital status (i.e. alive, dead, or emi-
gration) and primary therapy started within one year after
diagnosis (i.e. no anti-neoplastic therapy — including active
surveillance and lymph node excision — radiotherapy alone,
or treatment with a chemotherapeutic backbone) was avail-
able in the NCR. Data on the application of rituximab and
the exact therapeutic regimen were registered in the NCR for
patients diagnosed from 2007 and 2014 respectively (Dinmo-
hamed et al., 2017). The Privacy Review Board of the NCR
approved the use of anonymous data for this study.
Relative survival (RS) was calculated to estimate disease-
specific survival according to the cohort method (Dickman
& Adami, 2006). RS is defined as the ratio of the overall sur-
vival (OS) of patients to the expected survival (ES) of an
equivalent group from the general population, matched to
the patients by age, sex and time period. ES was estimated
from Dutch population life tables using the Ederer II method
(Ederer & Heise, 1959). RS was calculated up to ten years
after diagnosis according to calendar period (1993–2002 and
2003–2016), sex, age (18–39, 40–59, and ≥60 years), and
stage (I/II and III/IV). The first and last calendar periods
represent the pre- and post-rituximab era, respectively. Mul-
tivariable evaluation of RS was performed using Poisson
regression to assess the relative excess risk of mortality within
ten years after diagnosis (Dickman et al., 2004). Also, OS
was calculated up to ten years after diagnosis to present out-
comes according to primary therapy stratified by stage.
P < 005 indicated statistical significance. Seventy-one
patients <18 years at diagnosis were only included for inci-
dence analysis. Further details about the statistical analyses
are provided in the Data S1.
Results
Baseline patient characteristics are presented in Table SI.
Most patients were male (75%) and aged ≥40 years (51%),
and had stage-I/II disease (74%) and no B symptoms (70%).
Females were older than males (45 years vs. 39 years;
P = 0015). The overall age-standardized incidence rate
Fig 1. Primary therapy of adult patients with nodular lymphocyte-pre-
dominant Hodgkin lymphoma in the Netherlands according to stage
and age at diagnosis, 1993–2016. Panel A shows information on primary
therapy in broad categories for the entire study period of 1993–2016.
Panel B shows more detailed information on primary therapy for the
study period of 2014–2016. The absolute number of patients receiving a
particular treatment within a specific stage and age group is shown in
the graphs. The absolute number and proportion of patients within a
specific stage and age group are shown in Tables SII and SIII. ABVD,
doxorubicin, bleomycin, vinblastine, and dacarbazine; BEACOPP, bleo-
mycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procar-
bazine, and prednisone; R-CHOP, rituximab with cyclophosphamide,
doxorubicin, vincristine, and prednisone; R-CVP, rituximab with
cyclophosphamide, vincristine, and prednisone.
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Fig 2. Survival of adult patients with nodular lymphocyte-predominant Hodgkin lymphoma in the Netherlands, 1993–2016. Relative survival is
shown for the following categories: (A) calendar period of diagnosis, (B) sex, (C) age group, and (D) stage. The tables presented in panels A to
D show the projected five- and ten-year relative survival rates (RSRs) with 95% confidence intervals (CIs). Overall survival according to primary
therapy among patients with stage-I/II and -III/IV disease is shown in panels E and F, respectively. The projected five- and ten-year overall sur-
vival with 95% CIs are presented in Table SV. CIT, chemoimmunotherapy; CT, chemotherapy; RT, radiotherapy; R-mono, rituximab monother-
apy.
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increased from 10/1 000 000 to 22/1 000 000 person-years
between 1993–2002 and 2003–2016 respectively. This was a
result of the increasing incidence among adults (Figure S1).
Moreover, the median age increased from 34 to 42 years
between 1993–2002 and 2003–2016 respectively (P < 0001).
NLPHL mainly affects young and middle-aged adults
(Figure S2).
There were no noteworthy trends in primary therapy over
time among adult patients across the different disease stages
and age groups (data not shown). Overall, radiotherapy
alone was the treatment of choice in limited-stage disease
(i.e. stage I/II), whereas therapy with a chemotherapeutic
backbone was preferred in advanced-stage disease (i.e. stage
III/IV; Fig 1A and Table SII). This was independent of age.
Of note, patients with stage-I disease more often received
radiotherapy alone than those with stage II disease (62% vs.
46%; P < 0001). Chemotherapy was combined with radio-
therapy among 45% and 9% of the chemotherapy recipients
with limited- and advanced-stage disease, respectively
(P < 0001). During 2007–2016, 40% and 57% of the
chemotherapy recipients with limited- and advanced-stage
disease received chemotherapy with rituximab (P = 0095).
The application of rituximab remained comparatively steady
during this period. Lastly, rituximab monotherapy was rarely
applied. Detailed data of 143 adult patients diagnosed during
2014–2016 (median age, 50 years; age range, 18–81 years)
revealed that 84% of the chemotherapy recipients were trea-
ted with ABVD [Adriamycin (doxorubicin), bleomycin, vin-
blastine, and dacarbazine; Fig 1B and Table SIII].
At a median follow-up of 77 years (range, 01–250), 85
(14%) deaths occurred (median age at death, 65 years; range,
32–89 years). RS was generally excellent across the various
subgroups studied (Fig 2A–D). A particularly encouraging
finding was that patients aged 18–39 years experienced virtu-
ally no excess mortality, as compared to the general popula-
tion (Fig 2C). Also, excess mortality was comparatively low
among patients aged 40–59 and ≥60 years (Fig 2C).
The multivariable model, as shown in Table SIV, demon-
strated that RS was similar between the two calendar periods
(P = 0891) and sexes (P = 0477). As expected, the model
demonstrated a prognostic effect of age (P = 0005) and
stage (P < 0001). Interestingly, RS was similar between
patients aged 40–59 and ≥ 60 years (P = 0674).
OS according to the most frequently applied primary ther-
apy merits acknowledgement but not extensive description
(Figs 2E,F and Table SV). Ten-year OS (95% confidence
intervals) was 99% (96–100%) for adult patients with lim-
ited-stage disease who received radiotherapy alone and 80%
(67–88%) for those with advanced-stage disease who received
treatment with a chemotherapeutic backbone. Furthermore,
10-year OS (95% confidence intervals) was 80% (69–87%)
and 57% (35–74%) respectively among patients with limited-
and advanced-stage disease in whom no anti-neoplastic was
applied within the first year after diagnosis. Although limited
by small patient numbers, no deaths occurred at a median
follow-up of 54 years (range, 12–96 years) among the ten
recipients of rituximab monotherapy (median age, 36 years;
age range, 19–72 years).
Discussion
In contrast to a Swedish population-based study (Molin
et al., 2017) — but congruent with a US population-based
study (Shivarov & Ivanova, 2018) — we noted no sex-based
survival differences in NLPHL and no improved survival
after the implementation of rituximab into the therapeutic
armamentarium of NLPHL. Former studies showed that OS
was generally excellent in NLPHL (Molin et al., 2017; Shi-
varov & Ivanova, 2018; Borchmann et al., 2019). However,
for diseases with an indolent course, such as NLPHL, it is
appropriate to correct OS for the ES of the general popula-
tion; that is, RS (Dinmohamed et al., 2018). This is the first
study that assessed RS in NLPHL in a large population-based
cohort, showing that the great majority of patients with
NLPHL can look forward to a normal life expectancy. Excess
mortality in NLPHL might be related to its transformation
to a diffuse large B-cell lymphoma or late sequelae of ther-
apy. To date, strong evidence is lacking whether rituximab
could influence the transformation of NLPHL. Therefore,
since NLPHL is a rare disease, a large international study
with long-term follow-up is required to assess the effect of
rituximab on the transformation rate.
One of the main strengths of our study includes the use
of a nationwide population-based cancer registry with com-
prehensive information available for individual patients dur-
ing a 24-year period. Furthermore, in contrast to former
population-based studies, we calculated RS as a measure of
disease-specific survival. Limitations mainly pertain to the
lack of a central pathology review, detailed information on
treatment throughout most of the registry (1993–2013),
transformation and relapse rates, and information on cause
of death and treatment beyond one year after diagnosis.
In summary, in this large, contemporary, nationwide pop-
ulation-based study, the incidence of NLPHL increased over
time, likely due to enhanced awareness among clinicians and
pathologists for the diagnosis of NLPHL and improved diag-
nostic techniques. Survival among various subgroups of
NLPHL patients is largely comparable to the ES of the gen-
eral population. The implementation of rituximab in current
therapeutic regimens does not seem to have augmented sur-
vival in our cohort. Future prospective studies in NLPHL are
warranted to establish evidence-based treatment recommen-
dations that consider the delicate balance between efficacy,
toxicity, and quality of life.
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Data S1. Supplemental methods.
Fig S1. Age-specific incidence rates of patients with nodu-
lar lymphocyte-predominant Hodgkin lymphoma in the
Netherlands, 1993–2016. Incidence rates are presented per
1 000 000 person-years for the following age groups: 0–19,
20–39, 40–59, and ≥60 years. Incidence rates are shown for
(A) males and females together, (B) males alone, and (C)
females alone.
Fig S2. Age-specific incidence rates per quinquennial years
of age of patients with nodular lymphocyte-predominant
Hodgkin lymphoma in the Netherlands, 2003–2016. Inci-
dence rates are presented per 1 000 000 person-years and
shown according to sex. The period of 2003–2016 was cho-
sen, as this period in a way represents contemporary clinical
practice.
Table SI. Patient characteristics.
Table SII. Primary therapy of adult patients with nodular
lymphocyte-predominant Hodgkin lymphoma in the Nether-
lands according to stage at diagnosis, age at diagnosis, and
calendar period of diagnosis, 1993–2016.
Table SIII. Primary therapy of adult patients with nodular
lymphocyte-predominant Hodgkin lymphoma in the Nether-
lands according to stage and age at diagnosis, 2014–2016.
Table SIV. Excess mortality ratio during the first ten years
after the diagnosis of nodular lymphocyte-predominant
Hodgkin lymphoma.
Table SV. The projected five- and ten-year overall survival
among adult patients with nodular lymphocyte-predominant
Hodgkin lymphoma in the Netherlands according to primary
therapy and stage, 1993–2016.
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